TOWA PHARMACEUTICAL CO.,LTD. Logo

TOWA PHARMACEUTICAL CO.,LTD.

Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.

4553 | T

Overview

Corporate Details

ISIN(s):
JP3623150004
LEI:
Country:
Japan
Address:
門真市新橋町2番11号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TOWA PHARMACEUTICAL CO.,LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of generic drugs. Founded in 1951, the company is dedicated to providing high-quality and accessible medications. Its product portfolio encompasses a wide range of therapeutic areas, including drugs for the nervous system, digestive system, and allergic diseases, in addition to vitamins and antibiotics. The company focuses on formulation development to enhance its product offerings and contributes to healthcare by making essential medicines more widely available.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 01:01
Registration Form
確認書
Japanese 8.1 KB
2025-11-11 01:00
Interim Report
半期報告書-第70期(2025/04/01-2026/03/31)
Japanese 206.2 KB
2025-06-27 08:01
Regulatory News Service
臨時報告書
Japanese 24.0 KB
2025-06-24 05:01
Governance Information
内部統制報告書-第69期(2024/04/01-2025/03/31)
Japanese 23.6 KB
2025-06-24 05:00
Annual Report
有価証券報告書-第69期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2025-06-24 05:00
Registration Form
確認書
Japanese 8.1 KB
2024-11-13 01:01
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-13 01:00
Interim Report
半期報告書-第69期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-07-10 09:04
Registration Form
確認書
Japanese 8.1 KB
2024-07-10 09:00
Annual Report
訂正有価証券報告書-第68期(2023/04/01-2024/03/31)
Japanese 849.4 KB
2024-06-27 05:54
Post-Annual General Meeting Information
臨時報告書
Japanese 24.9 KB
2024-06-26 02:02
Regulatory News Service
内部統制報告書-第68期(2023/04/01-2024/03/31)
Japanese 21.7 KB
2024-06-26 02:01
Regulatory News Service
確認書
Japanese 8.1 KB
2024-06-26 02:01
Annual Report
有価証券報告書-第68期(2023/04/01-2024/03/31)
Japanese 1.4 MB
2024-02-14 01:01
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all TOWA PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TOWA PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TOWA PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
ARGENX SE Logo
Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.
United States of America ARGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.